Traditional Chinese Medicine Combined with Peginterferon α-2b in Chronic Hepatitis B: A Real-world Cohort Study
Peginterferon-α treatment exhibits low rates of the serological conversion rate of hepatitis B e antigen (HBeAg) and the negative conversion rate of hepatitis B virus (HBV) DNA, with significant myelosuppression leading to treatment discontinuation in some patients. Traditional Chinese medicine (TCM) may ameliorate liver inflammation and modulate immune responses. This study aims to investigate the efficacy of combining TCM with pegylated-interferon (PEG-IFN) α-2b and its impact on myelosuppression adverse effects.
Authors
- Manying Zhang (ORCID: https://orcid.org/0000-0002-8803-6707)
- Yubin Xie (ORCID: https://orcid.org/0000-0002-3566-4849)
- Luyun Zhang (ORCID: https://orcid.org/0000-0002-4787-3381)
- Min Hu (ORCID: https://orcid.org/0000-0002-0788-8765)
- Xiaoting Zheng (ORCID: https://orcid.org/0000-0003-3930-1049)
- Xiaowen Wu (ORCID: https://orcid.org/0000-0002-3728-2684)
- Yi Zheng (ORCID: https://orcid.org/0000-0003-1546-6973)
- Min Jia (ORCID: https://orcid.org/0000-0003-0390-8826)
- Shaodong Chen (ORCID: https://orcid.org/0000-0003-4727-5135)
- Huiqing Liang (ORCID: https://orcid.org/0009-0005-8447-6077)
- Yan Dai (ORCID: https://orcid.org/0000-0003-3279-5461)
Publication Details
- Journal
- Future Integrative Medicine
- Published
- 2025-09-18
- DOI
- https://doi.org/10.14218/fim.2025.00020
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- State Administration of Traditional Chinese Medicine of the People's Republic of China